doxorubicin hydrochloride

Product NDC
67184-0624
Requested package NDC
67184-0624-1
11-digit product format
671840624
Labeler code
67184
Product ID
67184-0624_c0fef14e-9c64-45d9-b2af-e78848559a25
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
doxorubicin hydrochloride
Dosage form
INJECTION, SUSPENSION, LIPOSOMAL
Route
INTRAVITREAL
Labeler
Qilu Pharmaceutical Co., Ltd.
Application
ANDA219881
Marketing category
ANDA
Marketing start
2026-02-03
Substance
DOXORUBICIN HYDROCHLORIDE
Active strength
2 mg/mL
Pharmacologic classes
Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A219881-001DOXORUBICIN HYDROCHLORIDEDOXORUBICIN HYDROCHLORIDE20MG/10ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-03
A219881-002DOXORUBICIN HYDROCHLORIDEDOXORUBICIN HYDROCHLORIDE50MG/25ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-03

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
A219881-001AB
A219881-002AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A219881-001DOXORUBICIN HYDROCHLORIDE20MG/10ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-03d4dbc9d85df4…
2026-11-14 07:37:172026-10A219881-002DOXORUBICIN HYDROCHLORIDE50MG/25ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-03d4dbc9d85df4…
2026-10-15 13:18:302026-09A219881-001DOXORUBICIN HYDROCHLORIDE20MG/10ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-03c2088c7a36db…
2026-10-15 13:18:302026-09A219881-002DOXORUBICIN HYDROCHLORIDE50MG/25ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-03c2088c7a36db…
2026-09-14 22:38:342026-08A219881-001DOXORUBICIN HYDROCHLORIDE20MG/10ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-0384e616aacf4f…
2026-09-14 22:38:342026-08A219881-002DOXORUBICIN HYDROCHLORIDE50MG/25ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-0384e616aacf4f…
2026-08-18 06:07:402026-07A219881-001DOXORUBICIN HYDROCHLORIDE20MG/10ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-03caaa826d4ba7…
2026-08-18 06:07:402026-07A219881-002DOXORUBICIN HYDROCHLORIDE50MG/25ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-03caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A219881-001DOXORUBICIN HYDROCHLORIDE20MG/10ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-03011fe1cb6892…
2026-02-19 14:30 UTC2026-02A219881-002DOXORUBICIN HYDROCHLORIDE50MG/25ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-03011fe1cb6892…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A219881-001DOXORUBICIN HYDROCHLORIDE20MG/10ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-03a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A219881-002DOXORUBICIN HYDROCHLORIDE50MG/25ML (2MG/ML)INJECTABLE, LIPOSOMAL / INJECTIONAB2026-02-03a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A219881-001AB1d4dbc9d85df4…
2026-11-14 07:37:172026-10A219881-002AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09A219881-001AB1c2088c7a36db…
2026-10-15 13:18:302026-09A219881-002AB1c2088c7a36db…
2026-09-14 22:38:342026-08A219881-001AB184e616aacf4f…
2026-09-14 22:38:342026-08A219881-002AB184e616aacf4f…
2026-08-18 06:07:402026-07A219881-001AB1caaa826d4ba7…
2026-08-18 06:07:402026-07A219881-002AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A219881-001AB1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A219881-002AB1011fe1cb6892…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A219881-001AB1a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A219881-002AB1a50c72e98297…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

Additional Listing Data#

Finished product
Yes
Brand name base
doxorubicin hydrochloride
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
DOXORUBICIN HYDROCHLORIDE2 mg/mL

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
82F2G7BL4EInternal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 2 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
1790115Internal RxNorm lookup
1790127Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
ed634b03-87cf-4a1c-a513-f34196dabd6fAvailable on FDA.report

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
doxorubicin hydrochlorideDOXORUBICIN HYDROCHLORIDEQilu Pharmaceutical Co., Ltd.ed634b03-87cf-4a1c-a513-f34196dabd6f2026-05-06Boxed warning, Warnings, Adverse reactionsExact identifier
application applno (ANDA): 219881
application number: ANDA219881
ndc (package): 67184-0624-1
ndc (product): 67184-0624
ndc11 (package): 67184062401
Doxorubicin Hydrochloride LiposomeDOXORUBICIN HYDROCHLORIDESagent Pharmaceuticalsc8eb4784-36e0-483f-9e5d-af0552e49bb52026-02-24Boxed warning, Warnings, Adverse reactionsExact identifier
application applno (ANDA): 219881
application number: ANDA219881

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startSampleExclude flagStatus
67184-0624-1671840624011 VIAL, SINGLE-USE in 1 CARTON (67184-0624-1) / 25 mL in 1 VIAL, SINGLE-USE2026-02-03NoNoCurrent